PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dexibuprofen→

Dexibuprofen PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
51146-56-6
Molecular formula
C13H18O2
Molecular weight
206.28 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)pharmacologically active S(+)-enantiomer of ibuprofen
Mechanism of action
A non-selective cyclo-oxygenase inhibitor that reduces prostaglandin synthesis, producing analgesic, anti-inflammatory and antipyretic effects; it also inhibits platelet aggregation.
Indications / reported uses
  • Symptomatic treatment of pain and inflammation in osteoarthritis
  • Primary dysmenorrhoea
  • Mild-to-moderate pain, including musculoskeletal pain, headache and toothache
  • Short-term symptomatic treatment of rheumatoid arthritis when disease-modifying therapy is not being considered; the cited UK SmPC includes adults and children/adolescents from 8 years

Sources: UK SmPC — Dexibuprofen 200 mg tablets (updated 6 Jun 2026) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Dexibuprofen PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dexibuprofen Permitted Daily Exposure (PDE) report (the Dexibuprofen PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dexibuprofen Occupational Exposure Limit (OEL) report (the Dexibuprofen OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.